Codex Committee on Residues of Veterinary Drugs in Foods (CCRVDF)

Codex Committee on Residues of Veterinary Drugs in Foods (CCRVDF)

24th Session - Chicago, United States of America, 23-27 April 2018

European Union comments on:

  • Agenda Item 6.2: Proposed draft MRLs for amoxicillin (finfish fillet, muscle); ampicillin (finfish fillet, muscle); flumethrin (honey), lufenuron (salmon and trout fillet), monepantel (cattle fat, kidney, liver, muscle) (CX/RVDF 18/24/6).
  • Agenda Item 10: Discussion paper on the evaluation of the rationale for the decline in new compounds to be included in the ccrvdf priority list for evaluation by JECFA (CX/RVDF 18/24/10).
  • CL 2016/41-RVDF: Priority List of Veterinary Drugs for Evaluation or Re-evaluation by JECFA
  • CL 2017/72-RVDF: Draft Risk Management Recommendation (RMR) for gentian violet
  • CL 2016/38-RVDF: Proposed draft MRLs for lasalocid sodium, ivermectin and teflubenzuron at step 5/8
  • CL 2016/39-RVDF: Proposed Draft RMR for Gentian Violet at Step 5

23rd Session - Houston, Texas, United States of America, 17–21 October 2016

European Union comments on:

  • Agenda item 5: Proposed Draft RMR for gentian violet at Step 3 (CL 2015/14-RVDF, Part B).
  • Agenda item 6: Proposed draft MRLs for ivermectin, teflubenzuron and lasalocid sodium.

22nd Session - San José, Costa Rica, 27 April – 1 May 2015

European Union comments on:

  • Agenda item 3: Matters Referred by the Codex Alimentarius Commission and other Committees - Codex Strategic Plan 2014-2019 (CX/RVDF 15/22/3).
  • Agenda item 6c: Proposed draft MRLs for derquantel, emamectin benzoate, ivermectin, lasalocid sodium and monepantel (CX/RVDF 15/22/6) and 'concern form' from for Lasalocid sodium.
  • Agenda item 6d: Proposed draft RMRs for dimitridazole, ipronidazole, metronidazole and ronidazole.

European Union reply to:

21th Session - Minneapolis, Minnesota, United States of America, 26–30 August 2013

European Union comments on:

  • Agenda item 6: Risk Management Recommendations for Residues of Veterinary Drugs for which no ADI and/or MRL has been recommended by JECFA due to Specific Human Health Concerns
  • Agenda item 7: Proposed draft Guidelines on performance characteristics for multi-residues methods
  • Agenda item 8b: Proposed "concern form" for the CCRVDF (Format and policy procedure for its use)

Archives